ESR1 and breast carcinoma: Atallah suggests that adjuvant anti-HER2 therapy after surgery can improve breast cancer-specific survival in patients with HER-2 IHC3+ tumors and ER-/HER-2 IHC2+ tumors, but it has no significant impact on patients with ER+/HER-2 IHC2+ tumors (4).